Breast Cancer
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
Latest News
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
Conference Coverage
Breast cancer experts and other HCPs disagree on treatment strategies for early BC
It’s challenging for some oncologists to keep up with the nuances of a rapidly changing field, said the author of new research.
News
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
Conference Coverage
Ribociclib forestalls recurrence also in early breast cancer
New results come from an interim analysis of a phase 3 randomized trial comparing maintenance therapy with ribociclib plus endocrine therapy with...
Conference Coverage
Phone support helps weight loss in patients with breast cancer
After 6 months, patients who received telephone coaching and health education lost 9.7 pounds.
Conference Coverage
Chemo avoidance pays off for some women with HER2+ early BC
Almost all patients who skipped chemotherapy avoided invasive disease/death at 3 years.
Conference Coverage
Breast cancer: Meta-analysis supports ovarian suppression/ablation
Controlling estrogen seems to give premenopausal women a lifespan boost, but strategy remains uncommon.
News
How a medical recoding may limit cancer patients’ options for breast reconstruction
The Centers for Medicare & Medicaid Services plans to reexamine how doctors are paid for a type of breast reconstruction known as DIEP flap....